NPD64: Nontraumatic Page kidney– A case report and literature review
蔡祐婷、沈元琦、王弘仁、李偉嘉、莊燿吉高雄長庚紀念醫院泌尿科
You-Ting Tsai, Yuan-Chi Shen, Hung-Jen Wang, Wei-Chia Lee, Yao-Chi Chuang Department of Urology, Kaohsiung Chang Gung Memorial Hospital
Purpose: Behavioral therapy is the first line treatment for overactive bladder (OAB) and the drug therapy is the second line treatment. The aim of this study is to evaluate the efficacy of behavioral therapy and different dosage of mirabegron, a β3-adrenoceptor agonist, combined with behavioral therapy in male patients with OAB.
Materials and Methods: In this multicenter, retrospective study, we assigned male adults with OAB into 3 groups (behavioral therapy, behavioral therapy plus mirabegron 25 mg per day and behavioral therapy plus mirabegron 50 mg per day). The diagnosis of OAB was defined as Overactive Bladder Symptoms Score (OABSS) questionnaire with total 3 or more points with an urgency score of 2 or more. Behavioral therapy is according to the lifestyle recommendation by the European Association of Urology for lower urinary tract symptoms. The primary outcome was the change in OABSS score from baseline to the end of the 12-week treatment in each group.
Results: A total of 280 patients were enrolled. At the end of the 12-week treatment, three groups showed significant improvement in OABSS total score (p<0.05), and there was no significant difference between each group. Urge urinary incontinence, nocturia and International prostate symptom score (IPSS) total score were significantly lower in three groups. IPSS-total, IPSS-storage scores and nocturia were significantly decreased in the group with Mirabegron 25 mg compared with other two groups. There was no negative impact of maximum flow rate (Qmax) and residual urine in the three groups.
Conclusions: In male patients with OAB, behavioral therapy and behavioral therapy plus mirabegron all showed significant improvement in OAB symptoms with no obvious negative impact on maximum flow rate and residual urine.